FFO
ATXS

Fortitude Family Office’s Astria Therapeutics ATXS Stock Holding History

Fortitude Family Office’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4
Closed -$21 – 2031
2025
Q1 		$21 Hold
4
– – ﹤0.01% 1140
2024
Q4 		$36 Hold
4
– – ﹤0.01% 1280
2024
Q3 		$44 Hold
4
– – ﹤0.01% 1202
2024
Q2 		$36 Hold
4
– – ﹤0.01% 958
2024
Q1 		$56 Hold
4
– – ﹤0.01% 964
2023
Q4 		$31 Buy
+4
New +$22 ﹤0.01% 1005

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Fortitude Family Office's ATXS Position: Q2 2025 in Review

Fortitude Family Office sold out of Astria Therapeutics (ATXS) in Q2 2025, closing a stake of 4 shares — an estimated $21 sold.

Fortitude Family Office first reported a position in ATXS in Q4 2023 and held it in 6 quarters. The position peaked at $56 in Q1 2024. 105 funds tracked by Wall St. Rank hold ATXS as of Q2 2025.

  • Fortitude Family Office reported no remaining Astria Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Fortitude Family Office sold 4 Astria Therapeutics shares in Q2 2025, an estimated $21.
  • Fortitude Family Office first reported a position in Astria Therapeutics in Q4 2023 and held it in 6 quarters.
  • Fortitude Family Office's Astria Therapeutics position peaked at $56 in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2025.

Based on Fortitude Family Office's 13F filing for Q2 2025, filed 15 Jul 2025.